The Role of Biobanks should be viewed in the context of ...

Biobanks | Sep 20071

IBM Healthcare & Life Sciences

© Copyright IBM Corporation 2007

Regulatory Agencies (FDA, EMEA, MHLW, WHO, DHHS, CDC)

PLarge PharmaOther PharmaIntegrated BiotechResearch Biotech

Drug Developers Patients/Consumers

DistMfrDevResearch

Large University/Medical SchoolsSpecialized Research CentersOther Academic Medical Research Centers (AMRC’s) and Biobanks

Integrated Delivery NetworksSpecialized HospitalsIndependent Community HospitalsPhysician Private Practices

Research Funding Agencies (NIH etc, EU FP, AP Gov'ts)

Equipment & Device CompaniesApplications ProvidersIT Infrastructure and Service ProvidersDiagnostics Manufacturers

Solution Providers Government (CMS, EU, AP) Private (US HMO’s: CIGNA, AETNA, Oxford Health, WellPoint, Kaiser Permanente, ...)Employers (Corporations)

Government Agencies

Patient (Genetic Alliance etc)Industry and Academic (e.g., Personalized Medicine Coalition, EPPOSI)

Advocacy Groups

The Role of Biobanks should be viewed in the context of the Healthcare and Life Sciences Ecosystem with the Patient/Consumer in the Center

Research Institutions

Healthcare Providers

Government Research

Payers

CROs (e.g. Quintiles, Parexel, Covance, Imaging Core Labs)

Clinical Trial Support




Clinical Patient Data must be integrated with Imaging, Genotypic, and Environmental Data to discover Biomarkers and to enable Biomarker based Pharma R&D and “Personalized Clinical Care”

Information Based Medicine

Bio

med

ical

Im

age

Dat

a

BasicResearch

Bio-Pharma R&D

ClinicalDelivery

Clin

ical

D

ata

HT

Res

earc

h D

ata

Env

iro.’a

lD

ata

Phenotype Genotype Environment

Molecular-level understanding of disease

Enabling development of Targeted Treatment

Solutions

Improving efficacy, safety and cost-efficiency of

patient care

PersonalizedClinical Care

Val

ue

Biobanks toBiomarkers




Medical/Biological Research (Biobank) Projects are aimed at the Discovery of new Biomarkers

The Mayo Clinic: Transform the effectiveness and economics of health care, by focusing on new techniques to harness patient data to improve diagnoses; deep computing power to model diseases to find cures; and new devices to access information to transform how patients and physicians interact, leading to more personalized care. Latest Step: MCLSS

Karolinska Institutet: The KI Biobank is an asset for biomedical research within fields such as genetics, functional genomics, as well as genetic and molecular epidemiology. KI Biobank benefit combines significant tissue collections and large national databases with epidemiological information. The robust and scalable Biobank Information Management System (BIMS) can readily accommodate a growing number of new projects and diverse data sources.

iCAPTURE/University of British Columbia: Determine the relationships between genomic, phenotypic, and environmental data in relation to heart, lung, and blood vessel disease. Focus on Imaging and Biomarker Discovery, including Tissue Rejection Biomarkers

In addition: AMC (Amsterdam), Danubian Biobank (Regensburg), St. Justine (Montreal), NIH Lupus Project, Taiwan Biobank ...




WS Information Integrator

WebSphere

Data Discovery and Query Builder

Query/Visualization/Analysis

MedicalInformationRepository

LaboratoryResults and

Reports

ClinicalNotes(20 M)

CodedDiagnostics

GeneExpression

CDA/XML

MAGE-ML

ETL

Replication

PatientDemo-

graphics

In the Medical Research Space, IBM has been partnering with leading institutions since 2002

MAYO Clinic High Level Architecture




BIM

S S

ervi

ces

BIM

S B

acke

nd A

rchitec

ture

In Partnership with IBM, KI Biobank developed the BIMS Architecture .....

StudyMgmt

SampleMgmt

DataQuery

DataCollection

Data Integration

BIM

S S

uppor

t Ser

vice

s

SecurityServices

PublicInfo

DataAnalysis

AdminServices

Original Data Sources

BIMS Data Repository

DataCategorization

6

IBM Global Business Services

© 2006 IBM Corporation

... recently enhanced to include Image Data Management (to address Stockholm Brain Institute IT requirements)

6

BIM

S S

ervice

sBIM

S S

ervice

sBIM

S S

ervice

sBIM

S B

acke

nd A

rchite

cture

BIM

S B

acke

nd A

rchite

cture

StudyMgmnt

DataQueryData

Query

Existing Data Integration

BIM

S S

uppor

t Ser

vice

s

SecurityServicesSecurityServices

PublicInfo

AdminServicesAdmin

Services

Existing Data Sources (Structured)

BIMS Data RepositoryBIMS Data Repository

DataAbstractionDataAbstraction

SampleMgmntSampleMgmnt

DataCollection

DataCollection

DataAnalysis

Web Portal

Content Manager

InformationIntegrator Content Edition

Records Manager




IBM Healthcare and Life Sciences Biobank Summits

• Nice, France: March 2004• - 40 attendees• - 30+ institutions

• Tarrytown, NY: November 2004• - 100+ attendees• - 90+ institutions




2005 WW Biobank Summits III and IV:Strategies to Address Next Generation Challenges for Biobanking

24-26 May 2005

The Nobel ForumKarolinska Institutet

Stockholm, Sweden

8-9 November 2005

“Quest for a Cure”Cooperation with NCI

Washington, DC

Web Resource: http://www.biobankcentral.org/public/index.php




By bringing together the various Stakeholders, IBM is hoping that the Imaging Biomarker Summits will accelerate the Transformation of Healthcare and Life Sciences

• The Imaging Biomarker Summits provide a Forum for the exchange of ideas and best practices related to Biomarker enabled Pharma R&D, with special emphasis on the impact of Imaging technologies. They are attended by representatives from Pharma, Biotech, Government & Academic Medical Research Centers, FDA, Medical Device Manufacturers and other IBM Partners.

• The Imaging Biomarker Summit feature presentations, facilitated Workshops, and Panel Discussions led by established academic and industry leaders

• Presentations at IBS I were given by- Peter Corr, Pfizer R&D- Carol Kovac, IBM HC & LS- Gerd Schmitz, Danubian Biobank- George Mills, FDA - Larry Schwartz, MSK Cancer Center

• Presentations at IBS II were be given by- Andrew von Eschenbach, FDA- Pfizer, Genentech, Merck & FNIH- NCI, UCLA, JHU, Wash U, U MD- GE HC, Siemens, Philips- IBM, VirtualScopics, Kitware

• Discussions of Imaging Biomarkers in Oncology, Neurosciences, and Cardiovascular disease

• Workshops, Panel Discussions- Imaging Biomarker Research / Discovery- Imaging Biomarkers in Pharma R&D- IT Standards and Architectures

• IBS Events 2007: IBS III (Nice) Jan 24-26, IBS IV (Japan) July 14-16

Participating OrganizationsPfizer, Merck, Novartis, J&J, AZ, Amgen, Roche, BMS, B-I, GSK, Roche/Chugai, Genentech, Wyeth, Astellas, Takeda, Eisai, PhRMA, FDA, GE, Siemens, Philips, NCI, NIH, NIST, FNIH, KI, Yale, MSK, Scripps, UCLA, JHU, Wash U, U MD, U Texas, Danubian Biobank, iCapture, Taiwan NCTU, NIRS, Tokyo Univ ...

Philadelphia | 26-27 June 2006Philadelphia | 26-27 June 2006

AMAGI | July 2007

Nice – La Gaude | January 24-26, 2007

IBS II

IBS III

IBS IV

The Role of Biobanks should be viewed in the context of ...

Documents